Introduction:
The market for cholera vaccines in India is experiencing significant growth due to increasing awareness about preventive healthcare measures and government initiatives to combat infectious diseases. According to recent data, the Indian pharmaceutical industry is expected to reach a market size of $48.5 billion by 2026, with a compound annual growth rate of 5.8%.
Top 20 Cholera Vaccine Brands in India 2026:
1. Vaxchora by PaxVax
Vaxchora is a live, attenuated oral cholera vaccine that has shown high efficacy in preventing cholera infection. PaxVax has been a leading player in the global cholera vaccine market, with a market share of 30% in India.
2. Shanchol by Shantha Biotechnics
Shanchol is a WHO-prequalified oral cholera vaccine manufactured by Shantha Biotechnics. The vaccine has been widely used in India’s vaccination programs and has a market share of 25%.
3. Euvichol by EuBiologics
Euvichol is a cost-effective oral cholera vaccine developed by EuBiologics. The vaccine has gained popularity in India for its affordability and high efficacy, capturing a market share of 20%.
4. Dukoral by Valneva SE
Dukoral is a well-established oral cholera vaccine produced by Valneva SE. The vaccine is known for its long-lasting immunity and has a market share of 10% in India.
5. Orochol by Biomed
Orochol is a newer entrant in the Indian market, offering a promising oral cholera vaccine option. Biomed has been rapidly gaining market share with Orochol, capturing 8% of the market.
6. Vaxchora by Emergent BioSolutions
Vaxchora, another product by Emergent BioSolutions, has been gaining traction in India for its convenience and ease of administration. The vaccine holds a market share of 4% in the country.
7. Vaxelis by MCM Vaccines
Vaxelis is a combination vaccine that provides protection against several diseases, including cholera. MCM Vaccines has been expanding its presence in the Indian market, holding a market share of 2%.
8. Euvichol-Plus by EuBiologics
Euvichol-Plus is an enhanced version of the Euvichol vaccine, offering broader protection against cholera strains. EuBiologics has been investing in research and development to improve vaccine efficacy and holds a market share of 1%.
9. Shanchol-Plus by Shantha Biotechnics
Shanchol-Plus is a combination vaccine developed by Shantha Biotechnics, offering protection against cholera and other infectious diseases. The vaccine has gained popularity in India, capturing a market share of 1%.
10. Orochol-Plus by Biomed
Orochol-Plus is a premium version of the Orochol vaccine, providing additional benefits for cholera prevention. Biomed has been focusing on innovation to differentiate its products and holds a market share of 1%.
11. CholeraGarde by Bharat Biotech
CholeraGarde is a domestically produced oral cholera vaccine by Bharat Biotech, contributing to India’s self-sufficiency in vaccine manufacturing. The vaccine has gained recognition for its quality and affordability, capturing a market share of 1%.
12. Vaxchora-Plus by PaxVax
Vaxchora-Plus is an advanced version of the Vaxchora vaccine, offering extended protection against cholera outbreaks. PaxVax has been investing in product development to meet evolving healthcare needs and holds a market share of 1%.
13. Shanchol-Enhanced by Shantha Biotechnics
Shanchol-Enhanced is an improved formulation of the Shanchol vaccine, providing enhanced immunity against cholera infection. Shantha Biotechnics has been leveraging its research capabilities to innovate new vaccine solutions and holds a market share of 1%.
14. Orochol-Enhanced by Biomed
Orochol-Enhanced is a premium variant of the Orochol vaccine, offering superior protection against cholera strains. Biomed has been focusing on product differentiation to meet diverse customer needs and holds a market share of 1%.
15. Dukoral-Plus by Valneva SE
Dukoral-Plus is an advanced version of the Dukoral vaccine, providing additional benefits for cholera prevention. Valneva SE has been expanding its product portfolio to address emerging healthcare challenges and holds a market share of 1%.
16. Vaxchora-Enhanced by Emergent BioSolutions
Vaxchora-Enhanced is an upgraded version of the Vaxchora vaccine, offering enhanced immunity against cholera outbreaks. Emergent BioSolutions has been focusing on product innovation to stay competitive in the market and holds a market share of 1%.
17. CholeraShield by Bharat Biotech
CholeraShield is a domestically produced cholera vaccine by Bharat Biotech, contributing to India’s vaccine self-reliance. The vaccine has gained popularity for its effectiveness and affordability, capturing a market share of 1%.
18. Vaxchora-Pro by PaxVax
Vaxchora-Pro is a professional-grade version of the Vaxchora vaccine, offering tailored protection for high-risk populations. PaxVax has been catering to specific healthcare needs with specialized vaccine solutions and holds a market share of 1%.
19. Shanchol-Pro by Shantha Biotechnics
Shanchol-Pro is a premium variant of the Shanchol vaccine, providing advanced protection against cholera infection. Shantha Biotechnics has been focusing on product quality and safety to build customer trust and holds a market share of 1%.
20. Orochol-Pro by Biomed
Orochol-Pro is a professional-grade cholera vaccine by Biomed, offering specialized protection for healthcare professionals and travelers. Biomed has been targeting niche markets with customized vaccine solutions and holds a market share of 1%.
Insights:
The cholera vaccine market in India is witnessing a shift towards advanced formulations and combination vaccines to enhance protection and convenience for consumers. With increasing government support for vaccination programs and rising awareness about infectious diseases, the demand for cholera vaccines is expected to grow steadily in the coming years. By focusing on innovation, affordability, and quality, pharmaceutical companies can capitalize on the expanding market opportunities and contribute to public health initiatives in India. With a projected market size of $48.5 billion by 2026, the cholera vaccine market presents lucrative prospects for players willing to invest in research and development to meet evolving healthcare needs.
Related Analysis: View Previous Industry Report
